Ignite Creation Date:
2024-05-06 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03683082
Status:
UNKNOWN
Last Update Posted:
2018-09-25
First Post:
2018-09-20
Brief Title:
Oxygen Treatment and Pulmonary Arterial Hypertension
Sponsor:
George Papanicolaou Hospital
Organization:
George Papanicolaou Hospital
Study Overview
Official Title:
Acute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension Patients
Status:
UNKNOWN
Status Verified Date:
2018-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary arterial hypertension PAH is a disease characterised with significant morbidity and poor prognosis Dyspnoea and impaired exercise capacity are very common manifestations of the disease and result in significant impairment of patients quality of life Although hypoxemia is common among subjects with PAH published data on the effects of supplementary oxygen therapy on specific clinical outcomes among these patients are currently few while the existing data on the potential benefits of oxygen supplementation to treat exercise-induced hypoxemia in this patient population are even more controversial Based on the aforementioned the purpose of this prospective crossover clinical trial is to investigate the acute effects of supplemental oxygen administration on the a exercise capacity b severity of dyspnea c cerebral oxygenation b muscle oxygenation and e hemodynamic profile as compared to delivery of medical air sham oxygen in a group of patients with PAH during steady state cardiopulmonary exercise testing CPET
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None